A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis

Rodent models of cholestatic liver disease: a practical guide for translational research

(2021) Eva Gijbels et al.   LIVER INTERNATIONAL

Global chemical effects of the microbiome include new bile-acid conjugations

(2020) Robert A. Quinn et al.   NATURE

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

(2020) Ping An et al.   LIVER INTERNATIONAL

Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics

(2019) Amy G. Feldman et al.   Nature Reviews Gastroenterology & Hepatology

Obeticholic acid may increase the risk of gallstone formation in susceptible patients

(2019) Samer Al-Dury et al.   JOURNAL OF HEPATOLOGY

FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis

(2019) M. Sorribas et al.   JOURNAL OF HEPATOLOGY

Bile acid metabolites control TH17 and Treg cell differentiation

(2019) Saiyu Hang et al.   NATURE

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

(2019) Marcos Pedrosa et al.   Contemporary Clinical Trials

Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis

(2019) Xinyang Song et al.   NATURE

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers

(2019) Michael K. Badman et al.   Clinical Pharmacology in Drug Development

Comparative analysis on liver transcriptome profiles of different methods to establish type 2 diabetes mellitus models in Guangxi Bama mini-pig

(2018) Yanjun Wu et al.   GENE

BILIARY ATRESIA: Clinical and Research Challenges for the 21st Century

(2018) Jorge A. Bezerra et al.   HEPATOLOGY

CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia

(2018) Yasuhiro Hasegawa et al.   HEPATOLOGY RESEARCH

Bile duct ligature in young rats: A revisited animal model for biliary atresia

(2017) Matias Garrido et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

(2017) Philipp Schwabl et al.   JOURNAL OF HEPATOLOGY

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

(2017) David C. Tully et al.   JOURNAL OF MEDICINAL CHEMISTRY

A single-cell survey of the small intestinal epithelium

(2017) Adam L. Haber et al.   NATURE

Nuclear receptors and nonalcoholic fatty liver disease 1 1This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.

(2016) Matthew C. Cave et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

(2016) María Úbeda et al.   JOURNAL OF HEPATOLOGY

Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care

(2016) Shikha S. Sundaram et al.   LIVER TRANSPLANTATION

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

(2015) Len Verbeke et al.   AMERICAN JOURNAL OF PATHOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

The Interplay of the Gut Microbiome, Bile Acids, and Volatile Organic Compounds

(2015) Nidhi M. Sagar et al.   Gastroenterology Research and Practice

Bile acids and the gut microbiome

(2014) Jason M. Ridlon et al.   CURRENT OPINION IN GASTROENTEROLOGY

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

(2013) Len Verbeke et al.   HEPATOLOGY

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

(2012) Bo Kong et al.   HEPATOLOGY

Bile acid transporters and regulatory nuclear receptors in the liver and beyond

(2012) Emina Halilbasic et al.   JOURNAL OF HEPATOLOGY

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR

(2012) Anna C. Calkin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

(2011) Salvatore Modica et al.   GASTROENTEROLOGY

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

Hydroxysteroid dehydrogenases (HSDs) in bacteria – A bioinformatic perspective

(2011) Michael Kisiela et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Effects of Age and Region on Fecal Microflora in Elderly Subjects Living in Bama, Guangxi, China

(2010) Liang Zhao et al.   CURRENT MICROBIOLOGY

Biliary atresia

(2009) Jane L Hartley et al.   LANCET

Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray

(2007) Hiroyuki Higashiyama et al.   ACTA HISTOCHEMICA